Advice

About this briefing

About this briefing

Medtech innovation briefings summarise the published evidence and information available for individual medical technologies. The briefings provide information to aid local decision‑making by clinicians, managers and procurement professionals.

Medtech innovation briefings aim to present information and critically review the strengths and weaknesses of the relevant evidence, but contain no recommendations and are not formal NICE guidance.

Development of this briefing

This briefing was developed for NICE by Newcastle and York External Assessment Centre. The interim process & methods statement sets out the process NICE uses to select topics, and how the briefings are developed, quality‑assured and approved for publication.

Project team

  • Newcastle and York External Assessment Centre

  • Medical Technologies Evaluation Programme, NICE.

Peer reviewers and contributors

  • Roseanne Jones, Research Scientist, Newcastle upon Tyne Hospitals NHS Foundation Trust

  • Derek Bousfield, Senior Clinical Technologist, Newcastle upon Tyne Hospitals NHS Foundation Trust

  • Matthew Dunn, Research Scientist, Newcastle upon Tyne Hospitals NHS Foundation Trust

  • Kim Keltie, Research Scientist, Newcastle upon Tyne Hospitals NHS Foundation Trust

  • Mick Arber, Information Specialist, York Health Economics Consortium

  • Helen Cole, Head of Service – Clinical Scientist, Newcastle upon Tyne Hospitals NHS Foundation Trust.

Specialist commentators

The following specialist commentators provided comments on a draft of this briefing:

  • Dr Jim Gray Consultant Microbiologist, Birmingham Children's Hospital NHS Foundation Trust

  • Ms Louise Hall, Matron in Infection Prevention and Control, Newcastle upon Tyne Hospitals NHS Foundation Trust

  • Professor John Perry, Clinical Scientist, Newcastle upon Tyne Hospitals NHS Foundation Trust

  • Professor Peter Wilson, Consultant Microbiologist, University College London Hospitals NHS Foundation Trust

  • Professor Neil Woodford, Head of Antimicrobial Resistance and Healthcare Associated Infections (AMRHAI) Reference Unit, Public Health England.

Declarations of interest

  • Professor John Perry has received funding for research or royalty payments from diagnostics companies, including bioMérieux and Lab M, which market competing products to Xpert Carba‑R

  • Professor Peter Wilson has acted as a consultant in rapid diagnostics to Momentum BioScience.

  • Professor Neil Woodford, as Head of Public Health England's AMHRAI Reference Unit, is actively engaged in assessing commercial systems for confirming carbapenemase production. He has been involved in commercially‑funded independent scientific evaluations including the Findlay et al. 2015 study. He is also involved in contract research for pharmaceutical and diagnostic companies, including Cepheid. He is in discussions with several companies, including Cepheid, about diagnostics for CPE.

Copyright

© National Institute for Health and Care Excellence, 2016. All rights reserved. NICE copyright material can be downloaded for private research and study, and may be reproduced for educational and not‑for‑profit purposes. No reproduction by or for commercial organisations, or for commercial purposes, is allowed without the written permission of NICE.

ISBN: 978‑1‑4731‑1668‑9